Liver disease
New drugs
On this page:
MaviretP,O
(new active substance)
Medical ingredient:
Glecaprevir, Pibrentasvir
Indication:
Maviret treats people with chronic (long-lasting) hepatitis C in adults. Hepatitis C is caused by an infection with the Hepatitis C virus (HCV).
For more information, see the Regulatory Decision Summary.
OcalivaP,O
(new active substance)
Medical ingredient:
Obeticholic Acid
Indication:
Ocaliva is used to treat primary biliary cholangitis (PBC).
For more information, see the Summary Basis of Decision.
Vemlidy
Medical ingredient:
Tenofovir Alafenamide Hemifumarate
Indication:
Vemlidy is used to treat chronic (long-lasting) hepatitis B in adults. Hepatitis B is caused by an infection with the hepatitis B virus (HBV)
VoseviP,O
(new active substance)
Medical ingredient:
Sofosbuvir, Velpatasvir, Voxilaprevir
Indication:
Vosevi is used to treat chronic (long-lasting) hepatitis C in adults who have:
- genotype 1, 2, 3, 4, 5, or 6 infection and have been previously treated with a type of medicine called an NS5A inhibitor
- genotype 1, 2, 3 or 4 infection and have been previously treated with sofosbuvir without another medicine called an NS5A inhibitor
For more information, see the Regulatory Decision Summary.
Page details
- Date modified: